Navigation Links
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Date:6/9/2009

SAN CARLOS, Calif., June 9 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to the position of Chief Medical Officer. Dr. Masuoka reports to Nektar's Senior Vice President, Drug Development and Chief Drug Development Officer, Randall Moreadith, M.D., Ph.D.

Dr. Masuoka has over 15 years of experience in clinical research and development. As Chief Medical Officer, she will be instrumental in helping to develop Nektar's clinical development strategy while continuing to oversee all clinical development functions, including Clinical Operations, Clinical Pharmacology, Drug Safety, Biometrics and Data Management. Dr. Masuoka joined Nektar in August 2008 as Vice President of Clinical Development.

"Lorianne's extensive clinical experience and superb guidance of our clinical development and operations teams make her an outstanding choice for Chief Medical Officer," said Randall Moreadith, M.D., Ph.D., Senior Vice President, Drug Development and Chief Drug Development Officer of Nektar, "Since joining Nektar, she has been instrumental in building our Drug Development group and assembling an internal Biometrics and Data Management Group, as well as streamlining our clinical operations."

Prior to Nektar, Lorianne was Vice President of Clinical Development at Five Prime Therapeutics where she led the advancement of a number of protein and antibody therapeutics in the areas of oncology, immunology and metabolic disease. Prior to that, Lorianne held senior leadership positions at Chiron and Berlex, where she was instrumental in development of Betaseron(R) for relapsing forms of multiple sclerosis as well as numerous oncology programs.

Dr. Masuoka received her M.D. from the University of California, Davis, completed a Fellowship
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Nektar Therapeutics Reports First Quarter 2009 Financial Results
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
5. Nektar Announces Retirement of Irwin Lerner from Board of Directors
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Inflamax Research Inc., ... Concept and Phase I-IV clinical trials, announced today ... Northern Air Environmental Technologies (NAET), a specialty air ... monitoring, and servicing of mobile Environmental Exposure Chambers ... trials. , Inflamax Research has ...
(Date:6/18/2013)... Monmouth, NJ (PRWEB) June 18, 2013 Earlier ... the AdWords advertising platform. As this directly impacts the ... to be the one of the most sweeping updates since ... Core and More Technologies recently posted a very informative ... initially set a ‘must-have’ upgrade date for enhanced campaigns ...
(Date:6/18/2013)... 18, 2013 NuView Life Sciences (NLS), ... in vitro diagnostic (IVD) biomarkers, today announced the results ... screen in development for the early detection of Prostate ... an oral presentation at the 2013 Annual Meeting of ... in Vancouver, Canada on Sunday, June 9th. NLS ...
(Date:6/17/2013)... FRANCISCO , June 17, 2013  KaloBios Pharmaceuticals, ... appointment of Donald R. Joseph as Chief ... years of biopharmaceutical industry experience and has worked in ... global health non-profit organizations. (Logo: ... successful track record as a general counsel and senior ...
Breaking Biology Technology:Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 2KaloBios Appoints Donald R. Joseph as Chief Legal Officer 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 4
... 21 Sequenom, Inc. (NASDAQ: SQNM ), a ... it will report financial results for the second quarter of ... August 4, 2011. A conference call hosted by ... members of senior management will take place on the same ...
... BioSciences, Inc. (Nasdaq: SGMO ) today announced that ... on Wednesday, July 27, 2011, after the market closes. The ... 5:00 p.m. ET, which will be open to the public ... will review the financial results and discuss other business matters. ...
... , Daval International announced the completion ... blind Phase II,Study, Treating Patients with Bladder Dysfunction ... clinical,measures and assessment scores recorded on patients who ... used to investigate safety,efficacy and response to treatment. ...
Cached Biology Technology:Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call 2Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast 2Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 2Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 3
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... new virus in patients with severe brain infections in ... virus is responsible for the symptoms of disease. , ... out of 644 patients with severe brain infections in ... any of the 122 patients with non-infectious brain disorders ... central nervous system are often fatal and patients who ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3
... weed is another man,s wonder and University of Guam research ... his career finding environmentally safe methods to control invasive plants. ... and coauthor of the book Biological Control of Tropical ... the Cambridge University Press and available to the public in ...
... signs of climate change in the upper atmosphere and ... Tyler Prize for Environmental Achievement. The award, ... will go to Richard Alley, professor of geosciences at ... atmospheric and climate sciences in the Scripps Institution of ...
... release is available in French and Spanish ... more than 160 endorsed science projects assembled from researchers in ... covers a two-year period to March 2009 to allow for ... joint project of WMO and ICSU, IPY spearheaded efforts to ...
Cached Biology News:Winners of Tyler environmental prize announced 2Polar research reveals new evidence of global environmental change 2Polar research reveals new evidence of global environmental change 3
Request Info...
QML offers standard and customized paraffin embedded tissue blocks....
Use our experts and resources to develop reagent systems for your applications....
Request Info...
Biology Products: